Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure

• Published in: Clinical pharmacokinetics 2021-08, Vol.60 (8), p.1061-1071
• Main Authors: Nabeta, Takeru, Kida, Keisuke, Ishida, Miwa, Shiono, Takaaki, Suzuki, Norio, Doi, Shunichi, Tsukahara, Maya, Ohta, Yuki, Kimura, Tetsuya, Yamaguchi, Keita, Takita, Atsushi, Matsumoto, Naoki, Akashi, Yoshihiro J., Ako, Junya, Inomata, Takayuki
• Format: Article
• Language: English
• Subjects: Anticoagulants; Atrial Fibrillation - drug therapy; Biomarkers; Cardiac arrhythmia; Cardiology; Clinical trials; Creatinine; Disease prevention; Drug dosages; Factor Xa Inhibitors; Heart failure; Heart Failure - drug therapy; Hemorrhage; Hospitalization; Humans; Informed consent; Internal Medicine; Laboratories; Medicine; Medicine & Public Health; Mortality; Original; Original Research Article; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Pyridines; Thiazoles
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/s40262-021-00999-y

Objective The objective of this study was to assess the pharmacokinetic and pharmacodynamic profiles and safety of edoxaban in patients with nonvalvular atrial fibrillation (NVAF) who were hospitalized with acute heart failure (AHF). Methods The trough plasma concentrations of edoxaban, and the coagulation biomarkers prothrombin fragments 1 and 2 (F1+2) and d -dimer, were determined. Twenty-six patients received edoxaban 60 mg (30 mg when dose adjustment was required) and blood samples were collected immediately before oral edoxaban administration for 7 consecutive days after hospitalization and on the day of discharge. Results The mean observation period was 13 (range 7–46) days. Trough plasma concentrations of edoxaban were constant from day 2 onwards. On day 1, the variation was greater owing to the differing intervals between the last edoxaban dose and day 1 blood collection. Trough plasma concentrations were higher in patients with reduced creatinine clearance (≤ 50 mL/min). Median values for F1+2 and d -dimer remained within normal ranges throughout the study. There were no drug discontinuations, and no serious adverse events were reported. Conclusions This is the first study of edoxaban pharmacokinetics and pharmacodynamics in patients with NVAF and AHF, and shows that the pharmacokinetic and pharmacodynamic profiles of edoxaban were constant during hospitalization. Thus, even in patients with NVAF and AHF, edoxaban anticoagulation therapy with guided dose adjustment is considered to be a safe and appropriate intervention. In particular, patients with reduced creatinine clearance should adhere to dose adjustment criteria. Clinical Trial Registration jRCTs031190006 (Japan Registry of Clinical Trials), 5 April, 2019 retrospectively registered.